Navigation Links
Inovio Pharmaceuticals Targets Transformation of Monoclonal Antibody Therapies
Date:9/24/2013

versity of Pennsylvania, Merck, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, University of Southampton, US Dept. of Homeland Security, University of Manitoba and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, i
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Inovio Pharmaceuticals to Present at Investor Conferences and Town Hall Los Angeles
2. Roche and Inovio Pharmaceuticals partner on Inovios prostate cancer and hepatitis B immunotherapy products
3. Inovio Pharmaceuticals to Present at Upcoming Investor Conferences
4. Inovio Pharmaceuticals Malaria DNA Vaccine Demonstrates Robust Immune Responses in Animal Models
5. Inovio Pharmaceuticals Reports 2013 Second Quarter Financial Results
6. Inovio Pharmaceuticals Responds to Market Activity
7. Inovio Pharmaceuticals Potent hTERT DNA Cancer Vaccine Shows Potential to Reduce Tumors and Prevent Tumor Recurrence
8. Synthetically Optimized HIF-1 Alpha DNA Delivered with Inovios Electroporation Technology Provides Significant Therapeutic Effects for Peripheral Arterial Disease in Animal Model
9. Todays Research: Inovio Pharma, Sequenom, Peregrine Pharma, Onyx Pharma, and Optimer Pharma
10. Inovio Pharmaceuticals to Present at OneMedForumNY 2013 Investor Conference
11. Inovios Universal H7N9 DNA Vaccine Generates First Protective Antibody Responses Against Virulent H7N9 Virus in 100% of Vaccinated Animals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/46q6x8/2015_strategies ... "2015 Strategies in the Home/Self Testing Market" ... 175-page report provides analysis of the major home/self ... pregnancy, ovulation, and occult blood. The report presents ... competitive profiles. The growing economic pressures ...
(Date:7/1/2015)...  Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY ), ... commercialization of proprietary compounded drug formulations, today announced ... market closing bell on Thursday, July 2, 2015.  ... Go Dropless™ campaign since its launch in April ... annually in the U.S. and more than 4.3 ...
(Date:7/1/2015)... 1, 2015 Lupin , ... Total Number of MPP Sub-licensees to Fourteen Companies ... (MPP) announced the rapid expansion of its network of generic ... projects to develop MPP-licensed antiretrovirals (ARVs). New companies Lupin and ... promising new HIV medicine the MPP licensed from ViiV Healthcare ...
Breaking Medicine Technology:2015 Strategies in the Home/Self Testing Market 2Imprimis Pharmaceuticals to Ring The Nasdaq Stock Market Closing Bell 2Imprimis Pharmaceuticals to Ring The Nasdaq Stock Market Closing Bell 3Imprimis Pharmaceuticals to Ring The Nasdaq Stock Market Closing Bell 4The Medicines Patent Pool Increases its Generic Manufacturing Network to Ramp-Up Production of Low Cost Antiretrovirals (ARVs) 2The Medicines Patent Pool Increases its Generic Manufacturing Network to Ramp-Up Production of Low Cost Antiretrovirals (ARVs) 3
... Oct. 12 mPay Gateway, the leader in ... the leader in software, services, information, and connectivity ... point-of-care patient payment technology to Allscripts practice management ... U.S. health care payment system is shifting to ...
... TEL AVIV, Israel, October 12 Elbit Imaging Ltd.,(NASDAQ: ... 9 ,2009 it sold a,total of 4,794,292 ordinary shares ... ("Plaza"), to a number of Polish,institutional investors. The aggregate ... million (approximately $10.6 million),representing a price of 6.5 Polish ...
Cached Medicine Technology:mPay Gateway Teams With Allscripts to Provide Point-of-Care Patient Payment Tools to Physician Practices Nationwide 2Elbit Imaging Ltd. Announces Sale of Plaza Centers Shares 2Elbit Imaging Ltd. Announces Sale of Plaza Centers Shares 3
(Date:7/1/2015)... Houston, TEXAS (PRWEB) , ... July 01, 2015 ... ... firm and solution provider of IBM software products, announced today that it has ... companies for the integration, display and detailed analysis of data from multiple sources ...
(Date:7/1/2015)... ... July 01, 2015 , ... Bunion ... sale. Customers purchasing two or more Bunion Booties directly from their website, ... Bunion Bootie temporarily corrects misaligned toes and its ultra thin properties allow for ...
(Date:7/1/2015)... ... 01, 2015 , ... B. E. Smith, the only full-service ... a national chief executive officer recruitment for Citizens Medical Center in ... B. E. Smith has recently placed more than 1,000 healthcare executives into organizations. ...
(Date:7/1/2015)... ... 01, 2015 , ... Incentivizing the use of generic drugs has been an ... as 80% or 90% off the prices for the brand-name products. But now that ... the financial impact of these high-cost generic drugs. The July issue of Atlantic Information ...
(Date:7/1/2015)... ... July 01, 2015 , ... ... global distribution and marketing of a number of nutritional and beauty products, announced ... the 2015 ECRM Diet, Vitamin & Sports Nutrition conference in Tampa, Florida. This ...
Breaking Medicine News(10 mins):Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 2Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 3Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 4Health News:Bunion Bootie, the #1 Non-Surgical Treatment for Bunion Pain, Announces Their Big Summer Sale 2Health News:Citizens Medical Center Retains B. E. Smith to Recruit New CEO 2Health News:Citizens Medical Center Retains B. E. Smith to Recruit New CEO 3Health News:Blues Execs Share Strategies for Managing Generic Drug Inflation in AIS Newsletter 2Health News:Blues Execs Share Strategies for Managing Generic Drug Inflation in AIS Newsletter 3Health News:NPI Executives Report Great Success at ECRM Conference 2
... 10 August, 2006) questions the government over a possible ?300 ... it warns, is already// under pressure on several different fronts. ... at least ?1 billion would be created for health research, ... and the NHS Research and Development programme. The combined value ...
... for a healthy body is what a new advertising campaign ... used mouthwashes// worldwide and in a recent advertisement running on ... for your mouth, think bigger." ,The mouthwash is used ... and kill germs between the teeth. , ,Member ...
... struck by an outbreak of anthrax and hundreds of them ... Agency has reported that nearly 118 animals in Manitoba have ... the effects of this outbreak on Humans, owing to the ... , ,The farms at Saskatchewan and area to ...
... comprised of Canada's postal service and several joint ventures, ... of who are represented by a postal workers' union. ... workforce challenges, but like nurses and mechanics, they are ... reported that diagnosed musculoskeletal complaints rose from 53 percent ...
... The latest study states that pre-menopausal women who are exposed ... ,The study that was a collaborative effort by ... US, and a team of Chinese researchers, was conducted on ... explained that they had measured the mineral density of the ...
... volunteers seriously ill has prompted scientists to device guidelines for ... the drugs firm AstraZeneca in a technique called "microdosing.", ... of the drug and will not get the drastic side ... ,"We can monitor at a local level if the tissue ...
Cached Medicine News:Health News:NHS research under pressure, and could face ?300 million cut, BMA warn 2Health News:Naturopathic Care and Low Back Pain 2Health News:Naturopathic Care and Low Back Pain 3Health News:Second-hand Smoke Could Increase The Risk Of Osteoporosis In Pre-menstrual Women 2
The new ProteomeX Workstation enables the rapid set up, execution and analysis of multidimensional LC/MS methods, providing you with the best possible technique to characterize your complex proteomic...
... over a wide range of concentration, ... more thorough characterization than other methods. ... relative change in the distribution of ... to measure heterogeneity, stoichiometry and self-associating ...
Storage temperature: 2 - 8C, linearity: 0 - 700 mg/dL, expected values: 30 - 780 mg/dL. Available with calibrator and number of tests 110....
Intended for the quantitative determination of triglycerides in serum or plasma. Reaction: endpoint, reaction is complete in five minutes at 37C. Wavelength: 540 nm. Linearity: 1000 mg/dL (11.3 mmol/...
Medicine Products: